Mubadala completed the acquisition of KELIX Bio.

Mubadala, an Abu Dhabi sovereign investor, completed the acquisition of KELIX Bio, a specialty pharmaceutical business focused on delivering complex generics across emerging markets. Financial terms were not disclosed. “In line with our role as a responsible investor, today’s acquisition is testament to the role Mubadala continues to play in accelerating the nation’s economic diversification through our portfolio companies and national champions,” Bakheet Al Katheeri, Mubadala CEO of UAE Investments Platform.